Skin Cancer Drugs Market Report 2026

Skin Cancer Drugs Market Overview

• Skin Cancer Drugs market size has reached to $5.3 billion in 2025 • Expected to grow to $9.12 billion in 2030 at a compound annual growth rate (CAGR) of 11.7% • Growth Driver: Sun Exposure And Tanning Habits Fueling Demand For Skin Cancer Drugs • Market Trend: Approval In Skin Cancer Drug Market • North America was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under Skin Cancer Drugs Market?

Skin cancer drugs refer to chemotherapy drugs that are used to treat skin cancer. Skin cancer refers to aberrant skin cell proliferation, which most frequently appears on sun-exposed skin. However, this prevalent type of cancer can also develop on parts of your skin that are not often exposed to sunlight. Skin cancer can be of various types including actinic keratoses, basal cell carcinoma, squamous cell carcinoma, or melanoma. Examples of skin cancer drugs include 5-FU, Aldara, and Efudex. The main types of skin cancer drugs are actinic keratoses (AK), basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma. Actinic keratoses are broad, rough skin patches that can turn cancerous. It commonly appears on sun-exposed regions such as the face, scalp, backs of the hands, and chest. It is especially common in fair-skinned persons. Solar keratosis and senile keratosis are two terms for the same condition. The different classes of drugs include chemotherapy, immunotherapy, targeted agents and other drugs and are used in various sectors such as hospitals, cancer research centers, and clinics.

What Is The Skin Cancer Drugs Market Growth Forecast?

The skin cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $9.12 billion in 2030 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to advancement in immunotherapy drugs, growing demand for targeted agents, increasing geriatric population, expansion of precision medicine, rising investment in cancer research. Major trends in the forecast period include rising adoption of immunotherapy and targeted drugs, increasing prevalence of non melanoma skin cancers, shift toward minimally invasive and topical treatments, growing focus on early diagnosis and preventive therapies, expansion of combination drug regimens.

Global Skin Cancer Drugs Market Segmentation

1) By Type: Actinic Keratoses (AK), Basal cell carcinoma (BCC), Squamous cell carcinoma (SCC), Melanoma 2) By Drug Class: Chemotherapy, Immunotherapy, Targeted Agents & Other Drugs 3) By End Users: Hospitals, Cancer Research Centers, Clinics Subsegments: 1) By Actinic Keratoses (AK): Cryotherapy Treatments, Topical Medications, Photodynamic Therapy (PDT), Laser Therapy 2) By Basal Cell Carcinoma (BCC): Surgical Excision, Mohs Micrographic Surgery, Radiation Therapy, Topical Therapies 3) By Squamous Cell Carcinoma (SCC): Surgical Excision, Cryosurgery, Electrosurgery and Curettage, Radiation Therapy 4) By Melanoma: Surgical Excision, Immunotherapy, Targeted Therapy, Chemotherapy and Radiation

What Is The Driver Of The Skin Cancer Drugs Market?

The increased sun exposure and tanning of individuals is expected to propel the growth of the skin cancer drug market in the coming years. Sun exposure is defined as the duration of time an individual spends in sunlight, which may have both beneficial and negative impacts on the skin and general health. Tanning is the darkening or discoloration of the skin caused by prolonged exposure to sunlight or additional sources of ultraviolet (UV) radiation. The skin diseases, especially skin cancer, coupled with advancements in treatment options and increasing awareness, contributes to the expansion of the skin cancer drugs market. For instance, in March 2024, according to the Australian Beraeu of Statistics, an Australia-based government agency, One in four (24.6%) people aged 15 years and over in Australia reported they would 'just burn and not tan' after 30 minutes of sun exposure. Additionally, two in five (38.1%) people aged 15 years and over used SPF30 or higher sunscreen on most days in late spring and summer 2023–24. Therefore, the increased sun exposure and tanning of individuals is driving the skin cancer drug industry.

Key Players In The Global Skin Cancer Drugs Market

Major companies operating in the skin cancer drugs market are Pfizer Inc., Meda Pharmaceuticals, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis International AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Mylan N.V., Daiichi Sankyo Company Limited, Bausch Health Companies Inc., Valeant Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Ipsen Pharma, LEO Pharma A/S, Aqua Pharmaceuticals, AB Science, Cellceutix Corporation, Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Seattle Genetics Inc.

Global Skin Cancer Drugs Market Trends and Insights

Major companies operating in the skin cancer drugs market are focusing on product approvals to better meet the needs of their existing demand. The rise in product approvals can be attributed to a combination of scientific advancements, regulatory changes, market demand, and patient advocacy. For instance, in March 2023, Incyte Corporation, a US-based pharmaceutical company that manufactures skin cancer drugs, announced that Zynyz (Retifanlimab-Dlwr) had been approved by the FDA for the treatment of metastatic or recurrent Merkel cell carcinoma (MCC). Zynyz (retifanlimab-dlwr), a monoclonal antibody made from human cells targeting programmed death receptor-1 (PD-1), is approved for the treatment of individuals with metastatic or recurrent locally advanced MCC. The US FDA accepted the Biologics License Application (BLA) for Zynyz for this indication under expedited approval based on tumor response rate and duration of response (DOR). Zynyz's continued clearance for this use may be conditional on the confirmation and description of therapeutic benefit in confirmatory studies.

What Are Latest Mergers And Acquisitions In The Skin Cancer Drugs Market?

In May 2025, Sun Pharmaceutical Industries Limited, an India-based pharmaceutical company, acquired Checkpoint Therapeutics, Inc., for an undisclosed amount. With this acquisition, Sun Pharma aims to expand its oncology portfolio, strengthen its pipeline of immunotherapy and targeted cancer treatments, accelerate the commercialization of key oncology assets, and enhance its overall presence in the global specialty medicines market. Checkpoint Therapeutics, Inc. is a US-based clinical-stage biopharmaceutical company, that offers skin cancer drugs.

Regional Insights

North America was the largest region in the skin cancer drugs market in 2025. Middle East is expected to be the fastest-growing region in the global skin cancer drugs market during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Skin Cancer Drugs Market?

The skin cancer drugs market consists of sales of vismodegib (Erivedge) and sonidegib (Odomzo). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Skin Cancer Drugs Market Report 2026?

The skin cancer drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the skin cancer drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.